You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Discovery of Zika virus therapeutics using a replicon assay

    SBC: MICROBIOTIX, INC.            Topic: R

    ABSTRACT The Zika virusZIKVis the cause of an explosive pandemic of infections across South and Central Americathe Caribbeanand the southeastern region of the United StatesZIKV is a flavivirusa family of small positive strand RNA viruses that includes Dengue virusDENVWest Nile virusWNVYellow fever virusYFVand hepatitis C virusHCVZIKV is transmitted to humans by mosquitoes of the Aedes genusFor the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors

    SBC: Panacise Bio, Inc.            Topic: 102

    Abstract This project seeks to develop the next generation pro CARs that are inactive in normal tissues but selectively activated in the tumor microenvironmentTMEThe project is based on our previous development of a novel class of chimeric antigen receptors on the basis of single domain antibody mimics that recognize ErbB family membersSDAErbBon the surface of cancer cellsWe propose two specific a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Intravascular molecular-structural NIRF-IVUS imaging of coronary artery disease

    SBC: IntraVascular Imaging, Inc.            Topic: NHLBI

    The goal of this Phase I STTR project is to constructoptimizeand test a clinically viable intravascular near infrared fluorescence intravascular ultrasoundNIRF IVUSimaging catheter for simultaneous molecular and structural diagnosis of coronary artery diseaseCADCAD is a worldwide leading cause of death and disabilityincluding acute myocardial infarctioncongestive heart failureand sudden cardiac de ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARY NETosis was identified as a distinct mode of cell death in neutrophils more than a decade agoDysregulation of NETosis has been implicated in the etiology of human pathologies such as preeclampsiasickle cell diseasesystemic lupus erythematosusmultiple sclerosisrheumatoid arthritissepsiscystic fibrosislupus nephritisand coagulopathies that include cancer associated thrombosisThe lite ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Reprogrammed T Cells to prevent graft versus host disease

    SBC: Element Genomics, Inc.            Topic: NIAID

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to develop an efficient and robust method to epigenetically reprogram na ve human T cells into regulatory T cellsTregsthat can prevent graft versus host diseaseGvHDOur short term goal for Phase I of the STTR award is to demonstrate that we can epigenetically reprogram na ve T cells using CRISPR Casbased technology into immunosuppressive ce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA

    SBC: COLLABORATIONS PHARMACEUTICALS, INC.            Topic: NIAID

    Project Summary The continued spread of drug resistant Mycobacterium tuberculosisMtbinfections has rendered tuberculosisTBa global health pandemic and pressed home the urgent need for new drugsCompounds which inhibit essential components of the Mtb cell wall rapidly cause cell death and are represented clinically by isoniazidIf any drug combination is likely to reduce treatment duration and preven ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Exploration of Low-Cost Long-Timescale Free Energy Perturbations on FPGAs

    SBC: Silicon Insite, Inc.            Topic: 400

    Drug discovery is challenging and expensiveespecially in the phase of lead optimization whichpredicts binding to a targetComputational approaches can add substantial valueComputingrelative binding free energiesRBFEbetween congeneric molecules using molecular dynamicsMDgreatly reduces the search space and considerably improves convergenceThe Silicon TherapeuticsSTXINSITE platform uses an RBFE proto ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government